The Current Ratio as of November 2024 (TTM) for BeyondSpring Inc. (BYSI) is 1.82

According to BeyondSpring Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.82. This represents a change of -11.90% compared to the average of 2.07 of the last 4 quarters.

BeyondSpring Inc. (BYSI) Historical Current Ratio (quarterly & annually)

How has BYSI Current Ratio performed in the past?

The mean historical Current Ratio of BeyondSpring Inc. over the last ten years is 4.63. The current 1.82 Current Ratio has changed 3.83% with respect to the historical average. Over the past ten years (40 quarters), BYSI's Current Ratio was at its highest in in the March 2017 quarter at 28.84. The Current Ratio was at its lowest in in the March 2015 quarter at 0.

BeyondSpring Inc. (BYSI) Current Ratio by Quarter and Year

Discovering the peaks and valleys of BeyondSpring Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BeyondSpring Inc. (BYSI) Average Current Ratio

How has BYSI Current Ratio performed in the past?

The current Current Ratio of BeyondSpring Inc. (BYSI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

BeyondSpring Inc. (BYSI) Current Ratio vs. Peers

How is BYSI’s Current Ratio compared to its peers?

BeyondSpring Inc.’s Current Ratio is less than Surrozen, Inc. (7.40), greater than Armata Pharmaceuticals, Inc. (0.19), less than Pasithea Therapeutics Corp. (14.81), less than Oncternal Therapeutics, Inc. (2.39), greater than Aditxt, Inc. (0.09), less than scPharmaceuticals Inc. (8.08), less than Milestone Pharmaceuticals Inc. (15.40), less than Oncolytics Biotech Inc. (2.99), greater than Seres Therapeutics, Inc. (1.12), less than aTyr Pharma, Inc. (6.07), greater than Kineta, Inc. (0.14), greater than Candel Therapeutics, Inc. (1.18), greater than MiNK Therapeutics, Inc. (0.89), less than Forte Biosciences, Inc. (2.06), less than AlloVir, Inc. (86.78), less than Ocuphire Pharma, Inc. (0), less than Reviva Pharmaceuticals Holdings, Inc. (10.68), greater than Protalix BioTherapeutics, Inc. (0.41), less than EyePoint Pharmaceuticals, Inc. (1.98), less than SELLAS Life Sciences Group, Inc. (5.50), less than null (2.26),

Build a custom stock screener for BeyondSpring Inc. (BYSI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BeyondSpring Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BeyondSpring Inc. (BYSI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BeyondSpring Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.